ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

BACKGROUND: Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only ~ 13 months. We have initiated the randomized placebo-controlled phase IIb study ALIC...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Transl Med
Autori principali: Kyte, J. A., Røssevold, A., Falk, R. S., Naume, B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310523/
https://ncbi.nlm.nih.gov/pubmed/32576225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02424-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi